Piscine Islet Xenotransplantation by James R. Wright & Jr.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
2 
Piscine Islet Xenotransplantation 
James R. Wright, Jr. 
University of Calgary Department of Pathology  
and Laboratory Medicine & Calgary Laboratory Services 
Canada 
1. Introduction 
In type I diabetes mellitus, the insulin-producing ǃ-cells have been destroyed by an 
autoimmune process and, thus, these patients are dependent upon daily insulin injections to 
sustain life; however, insulin injections are not a cure in that most patients eventually 
develop long-term complications due to imprecise control of blood glucose levels. Although 
one or more insulin injections, carefully coordinated with precise dietary and exercise 
regimens, can improve glycemic control, there is still considerable fluctuation of blood sugar 
levels throughout the day. Furthermore, excessive insulin administration can cause 
hypoglycaemia, coma, and brain damage. Insulin administration simply cannot provide the 
degree of glycemic control provided by the intact pancreatic islet. Normal islets function like 
thermostats except that they regulate blood glucose levels rather than temperature; islets 
recognize high or low blood glucose levels and respond by increasing or decreasing insulin 
secretion on a moment by moment basis, thus providing precise glycemic control 
throughout the day. There is considerable evidence that precise control of blood glucose 
levels will prevent the chronic complications of diabetes (Wolffenbuttel, 1993), and this is 
the primary rationale supporting pancreatic islet transplantation. 
Islet allotransplantation could allow for an actual “cure” for type I, and possibly also many 
patients with type II, diabetes; however, there are several perplexing problems (CITR 
Research Group, 2009). First of all, although considerable progress has been made with 
immunosuppressive regimens to promote islet allograft survival, long-term insulin 
independence occurs in less than 25% of patients; furthermore, there are potential 
complications associated with long-term immunosuppression. Therefore, islet 
allotransplantation is usually limited to type I diabetic patients who have difficulty 
controlling glycemic levels with insulin therapy and who have frequent hypoglycemic 
episodes. Second, in human (and mammalian) pancreases, islets comprise only 1-2% of the 
pancreas by volume and are scattered throughout. Isolating human islets is not an exact 
science. Currently, it often requires several human donor pancreases to obtain sufficient islets 
for a single transplant and the costs associated with each islet isolation procedure are huge. 
Third, and most importantly, there are simply an inadequate number of suitable human 
cadaveric donors. There are currently several million type 1 diabetic patients in North America 
and, each year, there are several tens of thousands of new cases; in stark contrast, there are less 
than ten thousand suitable donors per year. Thus, the supply of islets is a limiting factor that 
would likely prevent widespread application of clinical islet allotransplantation. 
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Clinical islet xenotransplantation, which could result in a potentially unlimited supply of 
donor islets, could be an attractive alternative. However, xenotransplantation creates an 
entirely new set of issues including: (1) selection of an appropriate donor species, (2) 
xenograft rejection, (3) risk of xenozoonotic disease transmission, (4) animal rights issues, (5) 
complicated ethical issues pertaining to the rights of recipients, close contacts, and society as 
a whole, (6) difficult institutional, national, and international regulatory issues, (7) very high 
potential costs, and (8) whether precious healthcare dollars could be better spent, especially 
in countries like Canada with public supported healthcare systems (Wright et al., 2004). This 
chapter will focus primarily on the selection of an appropriate donor but will touch on many 
of these other issues in passing. 
2. Experimental islet xenotransplantation using tilapia donors 
Unlike mammalians which have very large numbers of very small (microscopic) islets 
scattered amongst the exocrine pancreas (and comprising only 1-2% of its total volume), 
many teleost (i.e., bony) fish have small numbers of very large islets as discrete islet organs 
called Brockmann bodies. Because these large islets are macroscopically visible and easy to 
harvest, they actually played an important role in the discovery of insulin and have even 
been used sporadically over the past 90 years as a source of insulin for clinical treatment of 
diabetic patients (Wright, 2002a; Wright, 2002b). 
 
Fig. 1. The Nile Tilapia is a popular food world-wide. It is often produced in large 
aquaculture systems. A “market size” tilapia weighs about 700-800 grams. The maximum 
size, in our hands, is about 5kg (0.5 meter in length). Most of our transplant work is done 
with tilapia weighing between 500-1,200gm. 
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We have used tilapia (Oreochromis niloticus; figure 1), a large, commercially important warm 
water teleost species, as a source of islets for xenotransplantation research since 1992 
(Wright, 1992). We and others have shown that tilapia islets transplanted under the kidney 
capsules of streptozotocin-diabetic athymic nude mice provide long-term normoglycemia 
and mammalian-like glucose tolerance profiles (Wright et al., 1992; Morsiani et al., 1995; 
Leventhal et al, 2004). When transplanted into mice with a normal immune system, tilapia 
islet grafts are functionally and histologically rejected in 7-8 days (Wright et al., 1994) and 
graft rejection is characterized by massive infiltration of macrophages, eosinophils, and T-
cells (Wright et al., 1997). In general, tilapia islet xenograft rejection is temporally and 
mechanistically similar to rejection of pig or human islets (Dickson et al., 2003). 
2.1 Harvesting and transplanting tilapia brockmann bodies 
Harvesting tilapia islets is very simple; unlike mammalian islets, there is no need for 
inflating pancreatic ducts with expensive blends of special collagenases followed by 
complicated, time-consuming, and fickle islet isolation procedures. As shown in figure 2, 
Tilapia Brockmann bodies are scattered within the adipose tissue surrounding the common 
bile duct in a triangular region bounded anteriorly by the edge of the liver, superiorly by the 
stomach, and inferiorly by the spleen and gall bladder (i.e., “the Brockmann body region”). 
 
Fig. 2. Dissection of female tilapia with the right ovary and omentum (O) reflected 
downward reveals the roughly triangular Brockmann body region (outlined by arrows) 
surrounded by the liver (L), stomach (ST), and spleen (S) and gall bladder (G). LO=left 
ovary. Reprinted with permission from Yang H, Wright JR Jr. 1995. A method for mass 
harvesting islets (Brockmann bodies) from teleost fish. Cell Transplantation 4, pp. (621-628).  
www.intechopen.com
 Xenotransplantation 
 
22
The larger islets can be removed simply by excising the entire “region” (figure 3 & figure 4), 
placing it in a plastic petri dish with Hank’s Balanced Salt Solution, and microdissecting 
them from the adipose tissue while visualizing them with a dissecting microscope (Wright, 
1994). This method works fine but would be inefficient if doing more than a few transplants 
as it is slow and misses the smaller islets. Alternatively, the islets can be enzymatically mass-
harvested by removing regions from multiple fish simultaneously, placing them in a tube 
with a type II collagenase (normally used to harvest adipocytes) solution, and then placing 
the tube in a 370C shaker water bath for 10 minutes; when the incubation period is over, the 
digestion is stopped by adding cold Hank’s, causing the fat cells to float to the top of the 
tube and islets to remain as a pellet (Yang & Wright, 1995). 
 
Fig. 3. Excised Brockmann body “region” free floating in Hanks balanced solution salt 
solution. Reprinted with permission from Yang H, Wright JR Jr. 1995. A method for mass 
harvesting islets (Brockmann bodies) from teleost fish. Cell Transplantation 4, pp. (621-628). 
It should be noted that in large tilapia, some Brockmann bodies can measure up to 5 mm in 
maximum dimension [n.b., tilapia produce new islets and their older islets grow throughout 
their lifespan and so there is a tremendous range in islet size (Morrison et al., 2004)]. For our 
transplantation work, all large islets are broken up into smaller “mammalian islet” sized 
fragments (Yang et al., 1997a). After overnight culture, these fragmented islets “round up” and 
then take on the appearance of mammalian islets. Fragmented islets can then be transplanted 
immediately, cultured under various conditions (Wright & Kearns, 1995), or cryopreserved in 
liquid nitrogen (O’Hali et al., 1997). Fragmentation does not affect the cellular composition or 
function of the islets because the large islets are comprised of repetitive units similar to smaller 
islets (Yang et al., 1999a). There is a linear relationship between fish body weight and the 
number of islet endocrine cells (Dickson et al., 1998); therefore, the sum of the body weights of 
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multiple donor fish can be used to predict the total islet cell mass as well as the number of 
transplants that can be performed (Wright et al., 2004). 
 
Fig. 4. Whole mount produced by processing an entire Brockmann body region for 
histology. Sections were cut at three different levels through the block to provide a three-
dimensional view. Sections were stained with hematoxylin and eosin. The regions are 
composed of adipose tissue (A), bile and pancreatic ducts (D), blood vessels (V), nerve 
(N), and Brockmann bodies (BB). Twelve Brockmann bodies can be identified in the center 
frame. Reprinted with permission from Yang H, Wright JR Jr. 1995. A method for mass 
harvesting islets (Brockmann bodies) from teleost fish. Cell Transplantation 4, pp. (621-
628). 
In rodents, unencapsulated tilapia islets can be transplanted under the kidney capsule (Yang 
et al., 1997a), via the portal vein (Al-Jazaeri et al., 2005), or into the non-cryptorchid testes 
(Coddington et al., 1997). When islets are transplanted into any of these sites, the grafts 
undergo neovascularisation (i.e., recipient capillaries grow into the grafts). This is one of the 
features that makes islet transplantation different from whole organ transplantation, in 
which immediate direct vascular anastomoses are performed.  Because Brockmann bodies 
are discrete and separate from the exocrine pancreas, it is also possible to transplant them as 
immediately vascularised grafts by microvascular surgical techniques (Yu et al., 2003), 
creating the unique ability to compare these grafts as either neovascularized cell transplants 
or directly vascularised organ grafts. This is particularly interesting in the context that 
tilapia cells are too primitive to express ǂ(1,3) gal, an antigen expressed on mammalian cells 
(except human and Old World apes), that is responsible for hyperacute rejection of whole 
organ xenografts in man (Leventhal et al., 2004). Fish islets are also unique in that they can 
be transplanted into the non-cryptorchid testis; in contrast, mammalian islets only function 
if transplanted into the cryptorchid testis. The reason for this difference is that the fish are 
poikilotherms and their islets are fully functional at a wider range of body temperatures 
whereas mammalian islets require 370C. Tilapia islets are very well-suited for encapsulation 
(see below). 
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For experimental studies in which rejection is based upon monitoring function (i.e., ability 
to lower blood glucose levels), tilapia islets have a major advantage compared to either fetal 
or neonatal porcine islets, as the latter do not become functional until they have matured 
after transplantation. Tilapia islets, like adult pig islets, function immediately after 
transplantation. 
2.2 Xenotransplantation and xenograft rejection 
Initially, we used tilapia islets as an inexpensive tool to screen methods directed at 
preventing islet xenograft rejection.  The vast majority of early studies on islet xenografts 
were done with the concordant rat-to-mouse model and these studies implied that the islet 
xenograft rejection process could be easily circumvented (Wright & Yang, 1997). However, 
when methods that prevented islet xenograft rejection between concordant species were 
applied to discordant species combinations, most conferred little real protection. Intuitively, 
it seemed that it would be hard to imagine any species combination that would be more 
discordant than fish-to-mammal by virtue of the several hundred million years separating, 
these orders phylogenetically. The results of studies testing various modalities for their 
ability to prevent islet xenograft rejection have been reviewed elsewhere but, in general, we 
found that methods directed at decreasing graft immunogenicity prior to transplantation 
were ineffective but that chronic high dose immunosuppression was reasonably effective at 
prolonging islet xenograft survival(Wright & Yang, 1997; Wright & Pohajdak, 2001); 
however, the latter could precipitate post-transplant lymphoproliferative disorder (Yang et 
al., 2002b). We also developed a heterotopic heart transplant model to prove that 
xenotransplantation from tilapia to rodent was actually discordant (Yu & Wright, 1999). 
We also used the tilapia-to-mouse model to study the mechanism of xenograft rejection. 
Generally speaking, the mechanism of rejection of tilapia islets is highly CD4 dependent and 
appears to be no different than the rejection of pig islets (Dickson et al., 2003). Immune 
destruction of encapsulated tilapia islets (see below) in spontaneously diabetic NOD mice is 
also CD4 dependent (Xu et al., 2005). 
2.3 Xenotransplantation with encapsulation 
Encapsulation devices are small semi-permeable chambers in which islets can be placed 
prior to transplantation and which are designed to protect the islet grafts from the host’s 
immune system (de Vos et al., 2010; Vaithilingam & Tuch, 2011). These devices are generally 
divided into macroencapsulation and microencapsulation devices. Both achieve 
immunoprotection by creating a barrier with “pore” sizes small enough to prevent 
leukocytes and antibodies from damaging the graft but large enough for oxygen, insulin, 
glucose and nutrients to pass freely. Encapsulation devices, in general, have a number of 
associated problems including: (1) none are entirely biocompatible, (2) hypoxia causes graft 
attrition , (3) device durability issues, (4) pores can shed antigen precipitating inflammation, 
fibroplasia, and humoral sensitization, (5) cytokines can enter the pores, (6) devices must be 
replaced or refilled periodically, and (7) devices increase total graft bulk. 
Relative to mammalian islets, tilapia islets are highly resistant to hypoxia (Wright et al., 
1998b) making them ideal for incorporation into transplantable encapsulation devices (Yang 
& Wright, 2002a). We have previously shown that encapsulation markedly prolongs piscine 
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islet xenograft survival in small animal recipients (Yang et al., 1997) and that co-
encapsulation with allogenic or xenogeneic Sertoli cells further prolongs graft survival 
(Yang & Wright, 1999). Interestingly, the protective effect of Sertoli cells is not mediated by 
their Fas-ligand expression as Fas-L deficient Sertoli cells still confer protection (Yang et al., 
2002a).  
Dionne et al. (1994) have described the “idealized” islet for incorporation into encapsulation 
devices as follows. “The ideal tissue has a high insulin output, is correctly regulated by 
glucose and other secretogogues, has low metabolic demand, and is capable of functioning 
for extended periods without replacement. In addition, the cells must be procurable in high 
yield at reasonable cost with protocol meeting FDA standards (Dionne et al., 1994). In 
general, tilapia islets meet these criteria. However, to this definition, we would also add the 
need for a human insulin-like structure (see below). 
3. Potential clinical islet xenotransplantation using tilapia donors 
Because tilapia islets appear physiologically capable of providing long-term normoglycemia 
and mammalian-like glucose tolerance profiles, we believe that they could play a future role 
in clinical islet xenotransplantation. However, there are some significant issues.  
First of all, islets are not simply sources of insulin. Islets are comprised of multiple cell types 
which produce other hormones. In the context of a xenograft, it occurred to us that some of 
these foreign peptides might either have undesirable biological activity or, even if these 
other foreign peptides were non-functional, they might serve as antigens and promote 
antibody reactions as well as immune complex diseases. 
Second, little is known about how fish islets maintain normoglycemia. Before one could 
consider transplanting fish islets into humans, tilapia ǃ-cell physiology would need to be 
examined. 
Third, although it is known that fish insulins are functional in humans (Wright, 2002a; 
Wright, 2002b), their amino acid sequences usually differ considerably from that of human 
insulin and their relative biological activities in man are variable. Tilapia insulin structure 
differs from human insulin by a total of 17 amino acids (Nguyen et al., 1995), whereas, in 
contrast, porcine insulin differs at only the 30th amino acid on the B-chain.  
Fourth, although it was not known when we began this research, it is now believed that all 
fish possess two non-allelic insulin genes. Little is known about the Insulin-2 gene in tilapia 
or other fish.  
3.1 Other islet peptides 
Like mammalian islets, tilapia Brockmann bodies are mostly comprised of insulin-
producing ǃ-cells, glucagon-producing ǂ-cells, and somatostatin (SST)-producing δ-cells. 
However, there are some fundamental differences. First of all, the fourth primary peptide in 
mammalian islets is Pancreatic Polypeptide while in tilapia it is Peptide-YY; both typically 
represent 1-2% of the islet cells and will not be further discussed here.  Second, fish islets 
have two different types of δ-cells, one producing the 14 amino acid SST-1 (n.b., the 
sequence of this peptide is identical in all vertebrates) and the other a “large” SST, the 
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product of the preproSST-II gene (either not present or not expressed in mammals). Third, 
the percentages of the different cell types in mammals and tilapia differ greatly. In 
mammals, the insulin-producing ǃ-cells predominate (~70%), glucagon-producing ǂ-cells 
represent ~20%, and SST-producing δ-cells comprise <10%; in tilapia, the percentage of ǃ, ǂ, 
δ—1, and δ-2 cells are 42.3%, 11.5%, 21.8%, and 23.1% (Yang et al., 1999a). Fourth, the 
glucagon-producing ǂ-cells in fish simultaneous produce glucagon-like peptide (GLP)-1; 
mammals, in contrast, produce two different GLPs, GLP-1 and GLP-2, and GLP-1 is 
produced in the intestinal L-cells, while fish make only GLP-1, and it is produced only in the 
islet ǂ-cells. Fifth, in mammals, most islets are composed of a central ǃ-cell core and the non- 
ǃ-cells are at the periphery of the islet; in contrast each tilapia Brockmann body, which is 
much larger than mammalian islet, is comprised of many repetitive units containing a 
central core of ǃ-cells encased by a thin layer of SST-1 δ-cells which are surrounded by SST-2 
δ-cells and scattered -cells (Yang et al., 1999a). Because of this highly repetitive nature, 
Brockmann bodies fragmented for transplantation contain all cell types.  
These differences create several interesting scenarios related to xenotransplantation. First of 
all, in the context of the two different SSTs, SST-1 is 100% homologous with all mammalian 
SSTs, and, thus, should be biologically active while the second large SST would be 
biologically irrelevant and likely antigenic and could potentially precipitate immune 
complex disease. However, after xenotransplantation into streptozotocin-diabetic nude 
mice, the cells producing this peptide, the δ-2-cells, decreased from roughly 25% of the cells 
in the islet graft to negligible numbers in less than 2 months, apparently due to apoptosis 
secondary to the lack of any piscine trophic stimulation after xenotransplantation into a 
mammalian environment (Morrison et al., 2003b). Equally interesting was the observation 
that the percentage of the various endocrine cell types in the grafts became increasingly 
mammalian-like as time passed (Morrison et al., 2003b).  One further observation was that 
co-expression of GLP-1 and glucagon persisted throughout the study. This is intriguing as 
GLP-1 is known to promote improved glucose homeostasis and ǃ-cell neogenesis, which 
could be an advantageous by-product of fish islet xenotransplantation. 
3.2 Glucose homeostasis and β–cell function in tilapia 
Until recently, little was known about glucose homeostasis in fish. This is probably not 
surprising as there are very few fish species in which glucose is a significant component of 
their natural diets. In fact, it was generally believed that fish islets were not particularly 
glucose responsive (Wright et al., 2000). However, a simple xenotransplantation study using 
tilapia islets disproved this. In this study, glucose tolerance tests were performed in intact 
fish and it took them roughly 3 days to dispose of glucose loads, thus demonstrating 
extreme glucose intolerance (as had been shown previously in other fish species); however, 
when the tilapia islets were harvested from donor fish and engrafted under the kidney 
capsule of streptozotocin-diabetic nude mice, these same islets disposed of an equivalent 
glucose load in less than 30 minutes, suggesting that insulin secretion by tilapia islets was 
highly glucose-responsive but that the reason tilapia (and presumably other fish) were 
glucose intolerant was because of an extreme peripheral resistance to the glucostatic effects 
of insulin (Wright et al., 1998a). More recently, we have confirmed the glucose 
responsiveness of tilapia islets in vitro and have dissected the regulation of insulin gene 
expression and insulin production in tilapia islets (Hrytsenko et al., 2008). Interestingly, we 
also found insulin gene expression in the tilapia brain and pituitary (Hrytsenko et al., 2007). 
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Like in mammalian islets, the “glucose sensor” in the tilapia ǃ-cell is glucokinase (Joy, 2002). 
However, the glucose sensor must partner with a glucose transporter and we are less certain 
as to the primary glucose transporter in the tilapia ǃ-cell (Alexander et al., 2006; Hrytsenko 
et al., 2010). In rodent islets, GLUT-2 is the primary glucose transporter but in human islets 
it is GLUT-1. We have demonstrated high levels of expression of both transporters in tilapia 
Brockmann bodies; however, circumstantial evidence leads us to favor GLUT-1. 
Streptozotocin and alloxan are highly toxic to rodent ǃ-cells and induce severe diabetes; 
both are known to enter the ǃ-cell via GLUT-2 rather than GLUT-1; human ǃ-cells, which 
preferentially utilize GLUT-1, are highly resistant to both drugs. Tilapia ǃ-cells, like human 
ǃ-cells, are resistant to the diabetogenic effects of streptozotocin and alloxan (Wright et al., 
1999; Yang & Wright, 2002b; Xu et al., 2004). 
Alexander et al. (2006) have reviewed many other aspects of tilapia islet physiology. The 
readers are referred to this review for a more detailed analysis. 
3.3 Tilapia insulin structure and transgenic tilapia expressing a humanized insulin 
gene  
Although tilapia islets provide many advantages relative to mammalian islets, the tilapia 
insulin structure differs from human insulin structure by 17 amino acids and we felt that 
this would likely preclude their clinical use. Therefore, we decided to make and patent 
transgenic tilapia expressing a “humanized” tilapia insulin gene (Wright & Pohajdak, 2000; 
Wright & Pohajdak, 2002). This was accomplished by cloning and sequencing the tilapia 
insulin gene (Mansour et al. 1998), modifying it by site directed mutagenesis changing only 
the codons representing the 17 amino acids that differed between human and tilapia insulin, 
and then microinjecting the “humanized” tilapia insulin transgene via the micropile into 
fertilized tilapia eggs (Pohajdak et al., 2004). Resulting offspring were simultaneously 
screened by PCR using tilapia insulin gene-specific primers and humanized tilapia insulin 
gene-specific primers. One founder, who was later shown to be a mosaic (Wright et al., 
2008), demonstrated germ-line expression and passed the transgene on to some of his 
offspring. Positive offspring were segregated and grown to a size large enough to safely 
bleed and collect plasma for human insulin measurements. Some offspring with high levels 
of circulating human insulin were sacrificed for histology; figure 5 shows the presence of 
human insulin-positive ǃ-cells in a transgenic Brockmann body and absence of human 
insulin staining in ǃ-cells from a wild-type tilapia Brockmann body. Figure 6 shows that 
islet architecture (i.e., distribution of other endocrine cell types) is unchanged in transgenic 
tilapia islets. 
It should be noted, in order to maintain appropriate cleavage by the endopeptidases, the 
terminal amino acid on the B-chain was omitted and, therefore, our trangenics secrete 
[desThrB30] human insulin. In comparison, porcine insulin differs from human insulin by 
substitution of an Ala for the terminal Thr; whereas our transgenic human insulin is simply 
missing the terminal Thr. 
Eventually, while battling government regulatory and other nightmares (Wright, 2006; 
Wright et al., 2012), we were able to breed these transgenic fish to homozygosity and have 
now demonstrated lifelong transgene expression (Hrytsenko et al., 2010; Hrytsenko et al., 
2011). We hope to begin early pre-clinical transplantation studies soon. 
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Fig. 5. Histologic sections of pancreatic islets from control (A) and transgenic (B) juvenile 
tilapia. Sections are stained for human insulin by immunoperoxidase. Note the clusters of 
immunopositive ǃ-cells in the transgenic islets and the absence of staining in the control 
islets. Consistent results were obtained using several different commercially available 
monoclonal and polyclonal antibodies for human insulin. Reprinted with permission from 
Pohajdak B, Mansour M, Hrytsenko O, Conlon JM, Dymond C, & Wright JR Jr. 2004. 
Production of transgenic tilapia with Brockmann bodies secreting [desThrB30] human 
insulin. Transgenic Res. 13, 4, pp. (313-323). 
Eventually, we believe that we will need to either knockout the native tilapia insulin gene or 
at least silence it. Methods for producing gene knockout fish are still in their infancy with 
almost all of the work in this field having been performed in zebrafish or Japanese medaka. 
In general, the process, like in mice, will likely involve creating ES cells from tilapia 
blastulas at the ~1000 cell stage, knocking out the native tilapia insulin gene in vitro through 
homologous recombination, and then microinjecting these ES-cells back into developing 
(A)
(B)
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tilapia blastulas, screening for cutaneous chimerism, screening these chimeras for germ-line 
chimerism, and then breeding to homozygosity. Little of the work done in zebrafish and 
medaka is directly applicable and so we have done some of the preliminary work 
characterizing early embryogenesis in tilapia to facilitate these studies (Morrison et al., 2001; 
Morrison et al. 2003a) and have demonstrated the ability to make chimeras by 
microinjecting blastula cells (Wright et al., 2012). 
 
Fig. 6. Histologic sections of pancreatic islets from transgenic tilapia stained for human SST-
1 by immunoperoxidase. Note the concave shape of individual and small groups of SST-1+ 
δ-cells. These cells directly encase clusters of ǃ-cells and are surrounded by SST-2+ δ-cells 
(staining not shown here). The overall architecture of the Brockmann body is unchanged in 
transgenics. 
3.4 Two non-allelic insulin genes 
Recently, from studying genomic maps of zebrafish, medaka, and fugu (pufferfish), it has 
become apparent that ancestral fish underwent a genomic duplication several hundred 
million years ago and that these modern-day fish possess a second non-allelic insulin gene 
(Taylor et al., 2003). This may not be surprising as genome duplication appears to have 
played a major role in evolution as the “big leaps” cannot be explained by natural selection 
acting on necessary genes; big leaps required new gene loci with redundant function that 
could accumulate forbidden mutations (Conlon & Larhammar, 2005). Furthermore, such an 
insulin gene duplication would not be unique as it has long been known that rat and mouse 
islets express two non-allelic insulin genes (Lomedico et al., 1980) and there is even some 
evidence that the porcine insulin gene may be duplicated (Snel & Damgaard, 1980). 
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However, it critical to know whether tilapia have two non-allelic insulin genes and, if so, 
whether the second insulin gene is expressed and a product secreted as the transgenic 
tilapia that we produced by microinjecting a “humanized” tilapia insulin gene possess islets 
that simultaneously secrete both human insulin and tilapia insulin. Therefore, our plan is to 
knock out or silence the native tilapia insulin gene in these transgenics, resulting in donors 
with islets that secrete only human insulin. However, unless it has been deleted during 
evolution, it seemed highly probable that tilapia possess a second insulin gene and that, if it 
is expressed, this might adversely affect our ability to produce a donor strain with islets 
secreting only human insulin. 
Therefore, degenerative primers were designed based upon the alignment of the available 
sequences for fish insulin 2 genes and we cloned most of the NTins2 (nile tilapia insulin 2) 
gene and studied tissue-specific expression. Analysis of the primary protein organization 
revealed that the precursor molecule consists of the four typical preproinsulin regions: 
signal peptide, B chain, C chain, and A chain; prohormone convertase processing sites 
were determined and the peptide appeared to be potentially biologically active 
(Hrytsenko, 2007). 
Using qRT-PCR, we examined the levels of Insulin 2 gene expression in islets and other 
tissues and compared this with Insulin 1 gene and actin expression. Insulin 2 gene 
expression occurred in all tested tissues, except for adipose tissue, at exceedingly low levels, 
and the level of expression in tilapia islets was not significantly higher than in other tissues. 
This almost uniform pattern of insulin 2 expression resembles the expression pattern for 
house keeping genes, and is in contrast to the more tightly restricted ǃ-cell-specific 
transcription of the insulin 1 gene. It is most likely that the NTins2 gene is transcribed at low 
levels in essentially all extrapancreatic tissues and its transcription is only slightly up-
regulated in the pancreatic islets. Moreover, translation of the second insulin may actually 
be suppressed by the presence of a short reading frame upstream of the insulin initiation 
codon (Hrytsenko, 2007). Regardless, it seems unlikely that the insulin 2 product will need 
to be silenced in transgenic tilapia islets. 
4. Conclusions 
As documented above, tilapia islets have played a significant role in experimental islet 
xenotransplantation research. Advantages include ease of harvesting, total cost of 
procured islets, and the ability to transplant them into multiple body sites and have them 
function immediately after transplantation (not true for either fetal or neonatal pig islets); 
on the other hand, the major disadvantage is the need for specialized animal housing 
facilities, as aquatic facilities are not available at all research institutions. Transgenic 
tilapia islets expressing a humanized insulin gene may also play a role in future clinical 
islet xenotransplantation. We now have homozygous transgenics ready for pre-clinical 
testing. 
We conservatively estimate, based upon animal husbandry and islet isolation costs, that 
production costs for transgenic tilapia islets should be at least 100-fold less expensive than 
porcine islets on a per clinical transplant basis (Wright et al., 2004). This advantage could 
greatly facilitate the widespread implementation of clinical islet xenotransplantation as a 
cure for type I diabetes. 
www.intechopen.com
 Piscine Islet Xenotransplantation 
 
31 
5. Acknowledgment 
Financial support has been provided by the Juvenile Diabetes Research Foundation, the 
University of Calgary Faculty of Medicine, and Calgary Laboratory Services. 
6. References 
Alexander E, Dooley KC, Pohajdak B, & Wright JR Jr. (2006). Things we’ve learned from 
tilapia islet xenotransplantation. Gen. Com. Endocrinol. 148, 2, pp. (125-131) 
Al-Jazaeri A, Xu B-Y, Yang H, MacNeil D, Leventhal JR, & Wright JR Jr. (2005). Effect of 
glucose toxicity on intraportal tilapia islet xenotransplantation in nude mice. 
Xenotransplantation 12, pp. (189-196) 
Coddington DA, Lawen JG, Yang H, O'Hali W, & Wright JR Jr. (1997). Xenotransplantation 
of fish islets into the non-cryptorchid testis. Transplant. Proc. 29, pp. (2083-2085) 
Conlon JM & Larhammar D. (2005). The evolution of neuroendocrine peptides. Gen. Comp. 
Endocrinol. 142, pp. (53-59) 
CITR Research Group. (2009). 2007 update on allogeneic islet transplantation from the 
Collaborative Islet Transplant Registry (CITR). Cell Transplant. 18, 7, pp. (753-767) 
de Vos P, Spasojevic M, & Faas MM. (2010). Treatment of diabetes with encapsulated islets. 
Adv Exp Med Biol. 670, pp. (38-53) 
Dickson B, Yang H, Pohajdak B, & Wright JR Jr. (1998). Quantification of tilapia islets: a 
direct relationship between islet cell number and body mass. Transplant. Proc. 30, 
pp. (621-622) 
Dickson BC, Yang H, Savelkoul HFJ, Rowden G, van Rooijen N, & Wright JR Jr. (2003). Islet 
transplantation in the discordant tilapia-to-mouse model: a novel application of 
alginate microencapsulation in the study of xenograft rejection. Transplantation 75, 
pp. (599-606) 
Dionne K, Scharp D, Lysaght M Hegre P, & Lacy P. (1994). Macroencapsulation of islets for 
the treatment of diabetes. In: Lanza PR, Chick WL, eds. Pancreatic Islet Transplantation. 
Vol. 3. Immunoisolation of the Pancreatic Islets, RG Landes Co., pp. (119-131), Austin 
Hrytsenko O. (2007). Molecular characterization of the insulin genes in Nile tilapia 
(Oreochromis niloticus). PhD Dissertation, Dalhousie University, Halifax, Nova 
Scotia, Canada 
Hrytsenko O, Pohajdak B, & Wright JR Jr. (2010). Production of transgenic tilapia 
homozygous for a humanized insulin gene. Transgenic Res. 19, 2, pp. (305-306) 
Hrytsenko O, Pohajdak B, Xu B-Y, Morrison CM, van Tol B, & Wright JR Jr. (2010).  Cloning 
and molecular characterization of the Glucose Transporter 1 in tilapia 
(Oreochromis niloticus). Gen. Comp. Endocrinol. 165, 2, pp. (293-303) 
Hrytsenko O, Rayat G, Xu B-Y, Pohajdak B, Krause R, Rajotte RV, & Wright JR Jr. (2011). 
Lifelong stable human insulin expression in transgenic tilapia expressing a 
humanized tilapia insulin gene. Transgenic Res. – in press 
Hrytsenko O, Wright JR Jr, Morrison CM, & Pohajdak B. (2007). Insulin expression in the 
brain and pituitary cells of tilapia (Oreochromis niloticus). Brain Res. 1135, 1, pp. 
(31-40) 
Hrytsenko O, Wright JR Jr, & Pohajdak B. (2008). Regulation of insulin gene expression and 
insulin production in Nile tilapia (Oreochromis niloticus). Gen. Comp. Endocrinol. 
155, 2, pp. (328-340) 
www.intechopen.com
 Xenotransplantation 
 
32
Joy P. (2001).  Cloning, sequencing, and expression of the tilapia glucokinase. MSc Thesis, 
Dalhousie University, Halifax, Nova Scotia, Canada 
Leventhal JR, Sun JD, Zhang J, Galili U, Chong A, Baker M, Kaufman D, & Wright JR Jr. 
(2004). Evidence that tilapia islets do not express ǂ(1,3) Gal: Implications for islet 
xenotransplantation. Xenotransplantation 11, pp. (276-283) 
Lomedico PT, Rosenthal N, Kolodner R, Efstratiadis A, & Gilbert W. (1980). The structure of 
rat preproinsulin genes. Ann. N.Y. Acad. Sci. 343, pp. (425-432) 
Mansour M, Wright JR Jr, & Pohajdak B. (1998).  Cloning, sequencing and characterization 
of the tilapia insulin gene. Comp. Biochem. Physiol. 121B, pp. (291-297) 
Morrison CM, Miyake T, & Wright JR Jr. (2001). Development of embryo and early larva of 
Oreochromis niloticus (Pisces: Cichlidae). J. Morphol. 247, pp. (172-195) 
Morrison CM, Pohajdak B, Tam J, & Wright JR Jr. (2004). Development of the islets, exocrine 
pancreas and related ducts in the Nile tilapia, Oreochromis niloticus (Pisces: 
Cichlidae). J. Morphol. 261, pp. (377-389) 
Morrison CM, Pohajdak B, & Wright JR Jr. (2003a).  Structure and enzymatic removal of the 
chorion of embryos of the Nile tilapia Oreochromis niloticus. J. Fish Biol. 63, pp (1439-
1453) 
Morrison CM, Yang H, Al-Jazaeri A, Tam J, Plisetskaya E, & Wright JR Jr. (2003b). 
Xenogeneic milieu markedly remodels endocrine cell populations after 
transplantation of fish islets into streptozotocin-diabetic nude mice. 
Xenotransplantation 10, pp. (60-65) 
Morsiani E, Lebow LT, Rozga J, & Demetriou AA. (1995). Teleost fish islets: a potential 
source of endocrine tissue for the treatment of diabetes. J. Surg. Res. 58, pp. (583-
591) 
Nguyen T, Wright JR Jr, Nielsen PF, & Conlon JM. (1995). Characterization of the pancreatic 
hormones from the Brockmann body of the tilapia - implications to islet xenograft 
studies. Comp. Biochem. Physiol. 111C, pp. (33-44) 
O'Hali W, Yang H, Pohajdak B, LaPrairie A, Gross M, & Wright JR Jr. (1997). 
Cryopreservation of fish islets: the effect on function and islet xenograft survival. 
Transplant. Proc. 29, pp. (1990-1991) 
Pohajdak B, Mansour M, Hrytsenko O, Conlon JM, Dymond C, & Wright JR Jr. (2004). 
Production of transgenic tilapia with Brockmann bodies secreting [desThrB30] 
human insulin. Transgenic Res. 13, 4, pp. (313-323) 
Snel L & Damgaard U. (1988). Proinsulin heterogeneity in pigs. Horm. Metab. Res. 20, pp. 
(476-480) 
Taylor JS, Braasch I, Frickey T, Meyer A, & Van de Peer Y. (2003).  Genome duplication, a 
trait shared by 22000 species of ray-finned fish. Genome Res. 13, pp. (382-390) 
Vaithilingam V & Tuch BE. (2011). Islet transplantation and encapsulation: an update on 
recent developments. Rev Diabet Stud. 8, 1, pp. (51-67) 
Wolffenbuttel BH. (1993). The DCCT: “Metabolic control matters.” Diabetes Control and 
Complications Trial. Neth J Med. 43, 5-6, pp. (241-245) 
Wright JR Jr. (1992). Experimental transplantation using principal islets of teleost fish 
(Brockmann bodies). In: Pancreatic Islet Cell Transplantation: 1892-1992 - One Century 
of Transplantation for Diabetes, C Ricordi, RG Landes Co., pp. (336-351), Austin 
www.intechopen.com
 Piscine Islet Xenotransplantation 
 
33 
Wright JR Jr. (1994). Procurement of fish islets (Brockmann bodies). In: Pancreatic Islet 
Transplantation Series. Volume 1: Procurement of Pancreatic Islets, RP Lanza and WL 
Chick, RG Landes Co., pp. (125-135), Austin 
Wright JR Jr. (2002a). From ugly fish to conquer death: JJR Macleod’s fish insulin research, 
1922-24. The Lancet 359, pp. (1238-1242) 
Wright JR Jr. (2002b). Almost famous: E. Clark Noble, the common thread in the discovery 
of insulin and vinblastine. CMAJ 167, pp. (1391-1396) 
Wright JR Jr. (2006). Academic uses of GM fish technology: A call for a common sense 
approach to regulation. In: Assessment of Environmental and Indirect Human Health 
Effects of Genetically Modified Aquatic Organisms, RH Devlin, Canadian Technical 
Report of Fisheries and Aquatic Sciences 2581, Department of Fisheries & Oceans 
Canada, pp. (111-126), Ottawa 
Wright JR Jr, Abraham C, Dickson BC, Yang H, & Morrison C. (1999).  Streptozotocin dose 
response curve in tilapia, a glucose-responsive teleost fish. Gen. Comp. Endocrinol. 
114, pp. (431-440) 
Wright JR Jr, Bonen A, Conlon JM, & Pohajdak B. (2000).  Glucose homeostasis in the teleost 
fish tilapia: insights from Brockmann body xenotransplantation studies. American 
Zoologist 40, pp. (234-245) 
Wright JR Jr, Hrytsenko O, & Pohajdak B. (2012). Transgenic tilapia for islet 
xenotransplantation. In: Aquaculture Biotechnology, G. Fletcher and M. Rise, 
Blackwell Publications – in press 
Wright JR Jr & Kearns H. (1995). Long-term culture, low temperature culture, and hyperoxic 
culture do not prolong fish-to-mouse islet xenograft survival. Xenotransplantation 2, 
pp. (19-25) 
Wright JR Jr, Kearns H, Polvi S, MacLean H, & Yang H. (1994). Experimental 
xenotransplantation using principal islets of teleost fish (Brockmann bodies): Graft 
survival in selected strains of inbred mice. Transplant. Proc. 26, pp. (770) 
Wright JR Jr, Kearns H, Yang H, Fraser RB, Colp P, & Rowden G. (1997). 
Immunophenotyping fish-to-mouse islet xenograft rejection: A time course study. 
Ann. Transplant. 2, 3, pp. (12-16) 
Wright JR Jr, O'Hali W, Yang H, & Bonen A. (1998a). GLUT-4 deficiency and absolute 
peripheral resistance to insulin in the teleost fish tilapia. Gen. Comp. Endocrinol. 111, 
pp. (20-27) 
Wright JR Jr & Pohajdak B. (issued 1/18/2000). Transgenic fish and a method of harvesting 
islet cells therefrom. US Patent No. 6,015,713 
Wright JR Jr & Pohajdak B. (2001). Cell therapy for diabetes using piscine islet tissue. Cell 
Transplant.10, pp. (125-143) 
Wright JR Jr & Pohajdak B. (issued 11/5/2002). Transgenic tilapia comprising a humanized 
insulin gene. U.S. Patent No. 6,476,290 B1  
Wright JR Jr, Pohajdak B, Xu B-Y, & Leventhal JR. (2004). Piscine islet xenotransplantation. 
ILAR J. 45, pp. (314-323) 
Wright JR Jr, Polvi S, & MacLean H. (1992). Experimental transplantation with principal 
islets of teleost fish (Brockmann bodies): Long-term function of tilapia islet tissue in 
diabetic nude mice. Diabetes 41, pp. (1528-1532) 
Wright JR Jr, Snowden J, Hrytsenko O, Morrison CM, & Pohajdak B. (2008). 
Immunohistochemical staining for tilapia and human insulin demonstrates that a 
www.intechopen.com
 Xenotransplantation 
 
34
tilapia transgenic for humanized insulin is a mosaic. Transgenic Res. 17, 5, pp. (991-
992) 
Wright JR Jr & Yang H. (1997). Tilapia Brockmann bodies: An inexpensive, simple model for 
discordant islet xenotransplantation. Ann. Transplant. 2, 3, pp. (72-76) 
Wright JR Jr, Yang H, & Dooley KC. (1998b). Tilapia -A source of hypoxia-resistant islets for 
encapsulation. Cell Transplant. 7, pp. (299-307) 
Xu B-Y, Morrison CM, Yang H, & Wright JR Jr. (2004). Tilapia islets grafts are highly 
alloxan-resistant. Gen. Comp. Endocrinol. 137, pp. (132-140) 
Xu B-Y, Yang H, Serreze DV, MacIntosh R, Yu W, & Wright JR Jr. (2005). Rapid destruction 
of encapsulated islet xenografts by NOD mice is CD4 dependent and facilitated by 
B-cells: Innate immunity and autoimmunity do not play significant roles. 
Transplantation 80, pp. (402-409) 
Yang H, Al-Jazaeri A, & Wright JR Jr. (2002a). The immunoprotective effect of Sertoli cells 
co-encapsulated with islet xenografts is not dependent upon Fas-ligand expression. 
Cell Transplant. 11, pp. (799-801) 
Yang H, Dickson B, O'Hali W, Kearns H, & Wright JR Jr. (1997a). Functional comparison of 
mouse, rat, and fish islet grafts transplanted into diabetic nude mice. Gen. Comp. 
Endocrinol. 106, pp. (384-388) 
Yang H, McAlister VC, al-Jazaeri A, & Wright JR Jr. (2002b). Liposomal encapsulation 
significantly enhances the immunosuppressive effect of tacrolimus in a discordant 
islet xenotransplant model. Transplantation 73, pp. 710-713 
Yang H, Morrison CM, Conlon JM, Laybolt K, & Wright JR Jr. (1999a). Immunocytochemical 
characterization of the pancreatic islet cells of the tilapia (Oreochromis niloticus). 
Gen. Comp. Endocrinol. 114, pp. (47-56) 
Yang H, O'Hali W, Kearns H, & Wright JR Jr. (1997). Long-term function of fish islet 
xenografts in mice by alginate encapsulation. Transplantation 64, pp. (28-32) 
Yang H & Wright JR Jr. (1995). A method for mass harvesting islets (Brockmann bodies) 
from teleost fish. Cell Transplant. 4, pp. (621-p628) 
Yang H & Wright JR Jr. (1999).  Co-encapsulation of Sertoli enriched testicular cell fractions 
further prolongs fish-to-mouse islet xenograft survival. Transplantation. 67, pp. (815-
820) 
Yang H & Wright JR Jr. (2002). Microencapsulation methods: Alginate (Ca+2-induced 
gelation). In: Methods of Tissue Engineering, A Atala and R Lanza, Academic Press, 
pp. (787-801), New York 
Yang H & Wright JR Jr. (2002b). Human beta cells are exceedingly resistant to streptozotocin 
in vivo. Endocrinology 143, pp. (2491-2495) 
Yu W, Xu B-Y, & Wright JR Jr. (10/03/03). Directly vascularized pancreatic islet 
xenotransplantation: Is tilapia-to-nude mouse discordant? 7th International 
Xenotransplantation Congress, Glasgow, UK 
Yu W & Wright JR Jr. (1999). Heterotopic cardiac xenotransplantation: fish-to-rat. 
Xenotransplantation 6, pp. (213-219) 
www.intechopen.com
Xenotransplantation
Edited by Prof. Shuji Miyagawa
ISBN 978-953-307-997-4
Hard cover, 126 pages
Publisher InTech
Published online 03, February, 2012
Published in print edition February, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Accompanied by the advent of animal cloning, the technique of nuclear transfer produced alpha1,3-
galactosyltransferase-knockout (Gal-KO) pigs in many institutes, including the ones in Japan, at the beginning
of 21st Century. In addition, the controversy of the risks of PERV has gradually minimized, because of the fact
that there are no cases of PERV infections reported in humans. Furthermore, a large clinical wave for islet
allotransplantation resumed the interest of xenotransplantation, especially porcine islet transplantation and
some exceptions. Clinical trials were done in many countries so far, such as Sweden, China, Mexico, USA
(Inventory of Human Xenotransplantation Practices - IXA and HUG in collaboration with WHO). In addition, a
new clinical trial was approved by the government, and resumed the porcine islet transplantation research in
New Zealand two years ago.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
James R. Wright, Jr. (2012). Piscine Islet Xenotransplantation, Xenotransplantation, Prof. Shuji Miyagawa
(Ed.), ISBN: 978-953-307-997-4, InTech, Available from:
http://www.intechopen.com/books/xenotransplantation/piscine-islet-xenotransplantation
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
